BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study Posted on October 29, 2025 By admin Excellent news for our LGMD2I/R9 family! Link to GlobeNewswire’s article. Post navigation Previous: LGMD Scientific Workshop – Article PublishedNext: Cure Rare Disease Awarded $7.4 Million CIRM Grant to Advance Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9 admin Learn More →
